Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 150
- Registration Number
- NCT03517137
- Locations
- 🇳🇱
Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇵🇱Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03515707
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2023-02-24
- Target Recruit Count
- 18
- Registration Number
- NCT03467256
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 54
- Registration Number
- NCT03432598
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
- Conditions
- Recurrent Malignant Skin NeoplasmRecurrent Cutaneous MelanomaRecurrent Malignant Female Reproductive System NeoplasmRefractory Malignant Male Reproductive System NeoplasmRefractory Malignant Oral NeoplasmRecurrent Malignant Pharyngeal NeoplasmRecurrent Malignant Soft Tissue NeoplasmRecurrent Malignant Urinary System NeoplasmRefractory Cutaneous MelanomaRefractory Malignant Bone Neoplasm
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT03420963
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- Dietary Supplement: Ascorbic AcidDrug: CarboplatinDrug: DecitabineDrug: CisplatinDrug: CytarabineDrug: DexamethasoneDrug: EtoposideDrug: Gemcitabine HydrochlorideProcedure: Central Venous Cannula InsertionDrug: IfosfamideOther: Laboratory Biomarker AnalysisOther: Placebo AdministrationProcedure: Portacath PlacementOther: Questionnaire AdministrationBiological: RituximabDrug: OxaliplatinProcedure: Biospecimen CollectionProcedure: Core BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Computed Tomography
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 80
- Registration Number
- NCT03418038
- Locations
- 🇺🇸
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
🇺🇸Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
🇺🇸Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT03407144
- Locations
- 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 160
- Registration Number
- NCT03382561
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT03367143
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT03349346
- Locations
- 🇮🇹
Infantile Regina Margherita Hospital, Torino, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Italy
🇫🇷Centre Hospitalier Régional Universitaire de Lille, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.